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Background: The pathogenesis of idiopathic pulmonary arterial hypertension (IPAH) is
unknown, and the syndrome of IPAH remains a diagnostic and therapeutic challenge. The
present study investigated the disease-specific proteins that aid in the diagnosis of IPAH and
thus to study their role in the disease process.
Methods: A comparative proteomic analysis was used for clinical screening of serum proteins in
10 patients with IPAH and compared with 10 normal subjects. Furthermore, enzyme linked
immunosorbent assay (ELISA) was performed for comparison with serum proteins between indi-
vidual IPAH patients and controls.
Results: Nine proteins and their isoforms, including leucine-rich a-2-glycoprotein (LRG),
haptoglobin precursor, albumin isoform 2, transferrin variant, C3 complement, hydroxypyru-
vate reductase isoform 1, RAF1, fibrinogen isoformg-A and fibrinogen isoformg-B showed
significant changes in serum of IPAH patients compared with controls by proteomic analysis.
And significant higher serum levels of LRG in IPAH patients compared with controls were found
by ELISA. Correlation analysis disclosed a significant association between serum LRG concen-
trations and New York Heart Association (NYHA) functional class (rZ 0.71, P< 0.01) and
cardiac output (CO) (rZ0.65, P< 0.01).asic Research Program of China (973 program projects, program number: 2007CB512000, and project
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1802 J. Zhang et al.Conclusions: These results indicate that there are significant differences in the expression of
proteins in the serum of patients with IPAH and normal subjects. And the measurement of LRG,
RAF1 and C3 complement levels in the serum may be helpful for the diagnosis of IPAH. In
particular, LRG may be a specific prognostical biomarker of IPAH.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Idiopathic pulmonary arterial hypertension is a rare disease
of unknown etiology characterized by progressive elevation
of pulmonary arterial pressure (PAP).1 Although there was
a great improvement in survival with the development of
new therapies, IPAH is still a condition with high mortality
rates. The accurate assessment of prognosis in patients is
difficult. Moreover, the optimal timing for invasive proce-
dures such as atrial septostomy or lung transplantation
remains controversial that leads to a high mortality rate
among patients on the waiting lists. Many biomarkers have
been proposed as prognostic indicators in IPAH, including
uric acid,2 troponin T,3 big endothelin4 and brain natriuretic
peptide.5
IPAH is characterized by abnormal muscularization of
pulmonary arterioles, intimal thickening, and fibrosis,6 as
well as the presence of plexiform lesions, which are
believed to result from dysregulation of endothelial cell
growth.7 Mutations of the bone morphogenetic protein
receptor type II gene (BMPR2), a component of the trans-
forming growth factor beta (TGF-b) family which plays
a key role in cell growth, have been identified as causing
familial and sporadic forms of idiopathic pulmonary arterial
hypertension.8,9 Previous studies suggest that LRG interacts
with TGF-b receptor and modulates the activity of TGF-b10
and RAF proteins are a downstream response to growth
factors including TGF-b1.11
Proteomics is regarded as a complementary technology
to genomics and can be used to analyze body fluids such as
serum, urine, and cerebrospinal fluid. Proteomics offers
a completely new methodology for the analysis of compli-
cated biological and medical systems. The proteomic
approach allows the parallel evaluation of a large number
of components instead of just one or a few selected
markers, and is free of the bias caused by the pre-selection
of experimental targets. This is especially relevant if no
definite pathological hypothesis has to be proved or dis-
proved, but the aim is to attain a breakthrough in under-
standing physiological or pathological mechanisms. Two
dimensional gel electrophoresis (2-DE) in combination with
mass spectrometry (MS) has been widely used in cardio-
vascular fields.12,13
Here we describe our preliminary findings using proteo-
mic analysis to study the changes in the expression of serum
proteins in patients with IPAH. Our study found that
simultaneous analysis of the expression of 10 protein spots
could distinguish patients with IPAH from normal controls.
Furthermore, we also present a sensitive immuno-assay on
the level of LRG from patients with IPAH and controls and
the link between the variation of LRG levels and clinical
parameters.Methods
Patients
A total of 25 IPAH patients including 8 males and 17
females were included. The diagnosis of IPAH was estab-
lished according to the criteria of the National Institute of
Health registry.1 All patients underwent right heart cath-
eterization (RHC). Forty normal subjects were recruited as
normal control with matched age and sex. Informed
consent was obtained from each participant. The study
was approved by the Institutional Review Boards of Fu Wai
Hospital.
Serum samples
Blood samples were collected at baseline and were
centrifuged shortly after clot formation. All samples were
stored at 80 C in aliquots and thawed only before the
test. The serum albumin and IgG were removed using the
albumin and IgG removal kit (GE healthcare).
2-DE and MALDI-TOF-MS
To identify IPAH-specific proteins, serum samples from 10
patients with IPAH and 10 normal subjects were used. 2-DE
and matrix-assisted laser desorption/ionization time of
flight mass spectrometry (MALDI-TOF-MS) analysis were
performed as described in the supplemental section.
Enzyme linked immunosorbent assay
LRG was measured in serum samples with commercially
available sandwich ELISA kits (Quantikine, R&D Systems,
Minneapolis, MN, USA), following the manufacturer’s
instructions. The result was interpolated from the standard
reference curve provided with each kit. Each sample was
tested in duplicate and thawed only once.
Statistical analysis
Data were shown as the mean standard deviation (SD) or
as percentages. A 2-sided Student’s t-test was used to
evaluate different mean levels between two groups. The
Pearson correlation coefficient was used to evaluate the
correlation between the continuous variables. For all
analysis, a 2-sided P-value< 0.05 was considered as
statistically significant. All analyses were performed with
the Statistical Package for Social Sciences for Windows
(SPSS, Chicago, IL) version 14.0.
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The baseline haemodynamic pattern and the clinical char-
acteristics of the 25 patients enrolled in the study are listed
in Table 1.
Comparison of the silver-stained gels of the serum
samples from the 10 control subjects yielded almost iden-
tical protein expression profiles. The gels of the control and
IPAH proteins were digitized and analyzed by PDQuest
software. Comparison of the mean intensity of spots
between the 10 IPAH and 10 control gels identified signifi-
cant changes in 10 protein spots, representing 9 proteins.
These proteins were identified by MS as leucine-rich a-2-
glycoprotein, haptoglobin precursor, albumin isoform 2,
transferrin variant, C3 complement, hydroxypyruvate
reductase isoform 1, RAF1, fibrinogen isoformg-A and
fibrinogen isoformg-B. Two of them (haptoglobin and
fibrinogen) were expressed as multiple spots on 2-D gels,
suggesting that they were either charge isoforms or frag-
ments of the same protein. The altered protein spots are
highlighted in Fig. 1 and summarized in Table 2.
Measurable levels of LRG were found in both the IPAH
patients and the control subjects by the immunoenzymatic
technique. In IPAH group, LRG level in serum was
234.6 8.4 mg/mL (range, 189.3e345.2 mg/mL). In the
control group, the LRG level was 52.3 7.3 mg/mL (range,
32e75.4 mg/mL). Analysis of ELISA results indicates that the
LRG levels in IPAH patients are significantly higher than the
control subjects (P< 0.01) (Fig. 2). SerumLRG concentration
correlated with prognostically important variables, posi-
tively with NYHA functional class (rZ 0.71, P< 0.01), and
inversely with right cardiac output (CO) (rZ0.65,
P< 0.01). Interestingly, no correlations between serum LRG
concentration and meanPAP, pulmonary vascular resistance
(PVR), pulmonary capillary wedge pressure (PCWP), right
atrial pressure (RAP), troponin T or uric acid were found in
our group (Table 3).Table 1 Baseline clinical and haemodynamic data of IPAH
patients (nZ 25).
Age, yr 32.7 8.9
Sex, male/female 8/17
NYHA class IIIeIV, % 78.6
LVEF, % 62.3 12.5
CO, L/min 2.4 0.75
PVR, dyn cm5 m2 1639.1 840.6
PAPmean, mmHg 70.3 25
PCWP, mmHg 12.6 4.6
RAPmean, mmHg 9.9 5.2
RVPmean, mmHg 24.5 7.5
Uric acid, mmol/L 317.7 135.7
Troponin T, ng/mL 0.25 0.12
IPAH, idiopathic pulmonary arterial hypertension; NYHA, New
York Heart Association; LVEF, left ventricular ejection fraction;
CO, right cardiac output; PVR, pulmonary vascular resistance;
PAPmean, mean pulmonary arterial pressure; PCWP, pulmonary
capillary wedge pressure; RAPmean, mean right atrial pressure;
RVPmean, mean right ventricular pressure. Values are given as
the mean SD or No. (%).DiscussionThe present comparative proteomic approach based on
silver staining and MALDI-TOF-MS identified 10 changed
protein spots in the serum of patients with IPAH. Nine
proteins and their isoforms, including leucine-rich a-2-
glycoprotein, haptoglobin precursor, albumin isoform 2,
transferrin variant, C3 complement, hydroxypyruvate
reductase isoform 1, RAF1, fibrinogen isoform g-A and
fibrinogen isoform g-B, were affected. The subsequent
analysis indicated that LRG concentrations were signifi-
cantly higher in IPAH patients than the control subjects and
correlated with NYHA functional class and cardiac output.
These results suggest that the measurement of LRG, RAF1
and C3 complement levels in the serum may be helpful for
the diagnosis of IPAH. In particular, LRG may be a specific
prognostical biomarker of IPAH.
LRG was first identified as a trace protein in human
serum. The primary sequence of LRG includes leucine rich
repeat (LRR), a marked periodicity in the leucine residues
in this protein. The function of LRG has not been eluci-
dated, although the functions of many of the other
members of the LRR-containing superfamily are known.
Previous studies suggest that LRG interacts with TGF-
b receptor and modulates the activity of TGF-b.10 Hetero-
zygous germline mutations of BMPR2, a component of the
TGF-b-related family, is found to underlie up to 60% of
cases of familial IPAH.8,9 BMPR2 expression is documented
in plexiform lesions14 and in remodeled pulmonary arteries
in IPAH lungs, predominantly in endothelial cells. Despite
evidence supporting a loss of function for the TGF-b family
signaling, particularly in endothelial cells of IPAH, TGF-
b may produce gain-of-function alterations underlying
medial smooth muscle cell growth and adventitial fibroblast
activation. TGF-b is expressed in hypertensive pulmonary
arteries,15 and could signal via activation of smad 2 or 3,
whose expression was documented in pulmonary vascular
smooth muscle cells.16 TGF-b is known to increase the
synthesis of collagen, profibrotic proteins and extracellular
matrix protein production.17 Changes in extracellular
matrix composition contribute to progressive left ventric-
ular remodeling.18 Most importantly cardiac TGF-b has been
shown to be increased in patients with myocardial infarc-
tion, dilated cardiomyopathy and hypertrophic cardiomy-
opathy, cardiac conditions that are all associated with
increased heart failure.19e21 These results suggest that LRG
may be involved in the development of pulmonary hyper-
tension and heart failure through a possible interaction
with TGF-b. Increased levels of LRG in serum may be useful
for identifying and monitoring the progression of IPAH.
Complement C3 is produced by endothelial cells,
monocyte/macrophages, and fibroblasts.22 C3 is increased
in chronic inflammation and induces circulating monocytes
to express tissue factor, which is a potent procoagulant.23
In addition, C3d, a stable degradation product of C3b, plays
a major role in instructing the adaptive immune response,24
associated particularly with thrombosis. Under physiologic
conditions, in situ complement activation contributes to
the clearance of apoptotic cells from vascular lesions to
prevent necrosis and vascular damage associated with
thrombosis.
Figure 1 Photographs showing the serum proteins separated on pH gradient strips, followed by PAGE gels. The gels were stained
with silver staining. (a) Typical silver-stained 2D SDS-PAGE analysis of serum from patients with IPAH. (b) Regions of silver-stained
2D SDS-PAGE analyses from normal subjects and patients with IPAH. The numbers indicate the protein spots significantly changed in
intensity.
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enhance inflammation and influence the adaptive immune
response in the arterial wall. Complement derived inflam-
matory mediators likely play a role in vascular injury.25 In
our proteomic study, complement C3 levels were increased
in the serum from IPAH patients compared to control
subjects. These results suggest that in vivo settings were in
conditions with increased inflammation. Vascular pathologyleading to thrombosis is influenced by several recognized
risk factors including arterial injury, inflammation, and
activation of the adaptive immune response. Vascular
changes commonly seen in IPAH includemedial hypertrophy,
intimal hyperplasia, plexiform lesions, and small-vessel
thrombi. Local pulmonary thrombosis, likely initiated by
microscopic endothelial surface coagulation, is frequently
observed in patients with IPAH.26
Table 2 Identification of altered proteins in the serum of IPAH patients.
Spot no. IPI accession
number
Protein name Molecular
weight
pI Sequence
coverage (%)
IPAH/con ratio P value
1 IPI00478493 Haptoglobin protein 38427.3 6.13 28 2.57 <0.01
2 IPI00384697 Albumin isoform 2 47329.7 5.97 8 3.13 <0.01
3 IPI00219713 Fibrinogen isoformg-A 49465 5.7 26 1.95 <0.05
4 IPI00022417 LRG 38154.1 6.45 18 4.52 <0.01
5 IPI00641737 Haptoglobin precursor 46693.4 6.28 26 2.7 <0.01
6 IPI00477597 Hydroxypyruvate
reductase
isoform 1
38982.6 6.42 13 2.69 <0.01
7 IPI00783987 C3 complement 187029.9 6.02 2 5.97 <0.01
8 IPI00788857 RAF1 protein 15573 8.45 21 3.52 <0.01
9 IPI00798430 Transferrin variant 77029.6 6.68 25 1.53 <0.05
10 IPI0021891 Fibrinogen isoformg-B 51478.7 5.37 20 1.78 <0.05
pI, isoelectric point.
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induce growth and morphological transformation of estab-
lished cell lines. Subsequently it was discovered that acti-
vation of RAF proteins is a downstream response to growth
factors including TGF-b1 and is required to link growth
factor receptor signaling to activation of gene expression.11
RAF1 protein is one of 3 RAF isoforms in mammalians (ARAF,
BRAF and CRAF or RAF1). The interaction between GTPase
Ras and its downstream effector RAF1 is of crucial impor-
tance for the regulation of cell division and differentia-
tion.27 RAF1 has a critical role in controlling of cell cycle
progression by acting through mitogen-activated protein
kinases to induce protection against various apoptotic
stimuli.28 RAF1 upregulation may decrease apoptosis,
resulting in proliferation of the endothelial cell. FutureFigure 2 LRG levels in IPAH and controls. Each dot corre-
sponds to one subject studied. The horizontal bar indicates the
mean in each group.studies are needed to elucidate the pathophysiological role
of RAF1 in IPAH.
However, the method used in this study cannot be used
in clinical practice for the moment because of the high cost
of this new approach. The expression of other proteins such
as albumin isoform 2 (spot 2), hydroxypyruvate reductase
isoform 1(spot 6), and transferrin variant (spot 9) are also
altered in our patients. Their roles in the development of
IPAH remain to be further investigated.
In conclusion, our results indicate that there are signifi-
cant differences in the expression of proteins in the serum of
patients with IPAH and normal subjects. And the measure-
ment of LRG, RAF1 and C3 complement levels in the serum
may be helpful for the diagnosis of IPAH. In particular, LRG
may be a specific prognostical biomarker of IPAH.
Limitations
The present study has several limitations. First, cardiopul-
monary exercise tests, particularly the 6-minute walk test,
which is thought to be linked to IPAH patient prognosis, have
not been performed. Second, the lack of currently available
antibodies to RAF for ELISA has hindered the determination
of its concentration in the serum and its pathophysiological
role in IPAH. Further researches using antibody against RAF
should help to elucidate the value of RAF.Table 3 Correlations between selected baseline clinical
data and LRG levels in patients with IPAH.
Parameters r Value P value
Age 0.084 NS
NYHA class 0.71 <0.001
LVEF 0.16 NS
CO 0.65 0.008
PVR 0.275 NS
PAPmean 0.167 NS
PCWP 0.124 NS
RVPmean 0.216 NS
RAPmean 0.245 NS
Uric acid 0.196 NS
Troponin T 0.232 NS
Abbreviations as in Table 1; NSZ not significant.
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